RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. Rooney, N., Mason, S. M., McDonald, L., Däbritz, J. H. M., Campbell, K. J., Hedley, A., Howard, S., Athineos, D., Nixon, C., Clark, W., Leach, J. D. G., Sansom, O. J., Edwards, J., Cameron, E. R., & Blyth, K. Cancer Research, 80(11):2325–2339, June, 2020. doi abstract bibtex The recurring association of specific genetic lesions with particular types of cancer is a fascinating and largely unexplained area of cancer biology. This is particularly true of clear cell renal cell carcinoma (ccRCC) where, although key mutations such as loss of VHL is an almost ubiquitous finding, there remains a conspicuous lack of targetable genetic drivers. In this study, we have identified a previously unknown protumorigenic role for the RUNX genes in this disease setting. Analysis of patient tumor biopsies together with loss-of-function studies in preclinical models established the importance of RUNX1 and RUNX2 in ccRCC. Patients with high RUNX1 (and RUNX2) expression exhibited significantly poorer clinical survival compared with patients with low expression. This was functionally relevant, as deletion of RUNX1 in ccRCC cell lines reduced tumor cell growth and viability in vitro and in vivo. Transcriptional profiling of RUNX1-CRISPR-deleted cells revealed a gene signature dominated by extracellular matrix remodeling, notably affecting STMN3, SERPINH1, and EPHRIN signaling. Finally, RUNX1 deletion in a genetic mouse model of kidney cancer improved overall survival and reduced tumor cell proliferation. In summary, these data attest to the validity of targeting a RUNX1-transcriptional program in ccRCC. SIGNIFICANCE: These data reveal a novel unexplored oncogenic role for RUNX genes in kidney cancer and indicate that targeting the effects of RUNX transcriptional activity could be relevant for clinical intervention in ccRCC.
@article{rooney_runx1_2020,
title = {{RUNX1} {Is} a {Driver} of {Renal} {Cell} {Carcinoma} {Correlating} with {Clinical} {Outcome}},
volume = {80},
issn = {1538-7445},
doi = {10.1158/0008-5472.CAN-19-3870},
abstract = {The recurring association of specific genetic lesions with particular types of cancer is a fascinating and largely unexplained area of cancer biology. This is particularly true of clear cell renal cell carcinoma (ccRCC) where, although key mutations such as loss of VHL is an almost ubiquitous finding, there remains a conspicuous lack of targetable genetic drivers. In this study, we have identified a previously unknown protumorigenic role for the RUNX genes in this disease setting. Analysis of patient tumor biopsies together with loss-of-function studies in preclinical models established the importance of RUNX1 and RUNX2 in ccRCC. Patients with high RUNX1 (and RUNX2) expression exhibited significantly poorer clinical survival compared with patients with low expression. This was functionally relevant, as deletion of RUNX1 in ccRCC cell lines reduced tumor cell growth and viability in vitro and in vivo. Transcriptional profiling of RUNX1-CRISPR-deleted cells revealed a gene signature dominated by extracellular matrix remodeling, notably affecting STMN3, SERPINH1, and EPHRIN signaling. Finally, RUNX1 deletion in a genetic mouse model of kidney cancer improved overall survival and reduced tumor cell proliferation. In summary, these data attest to the validity of targeting a RUNX1-transcriptional program in ccRCC. SIGNIFICANCE: These data reveal a novel unexplored oncogenic role for RUNX genes in kidney cancer and indicate that targeting the effects of RUNX transcriptional activity could be relevant for clinical intervention in ccRCC.},
language = {eng},
number = {11},
journal = {Cancer Research},
author = {Rooney, Nicholas and Mason, Susan M. and McDonald, Laura and Däbritz, J. Henry M. and Campbell, Kirsteen J. and Hedley, Ann and Howard, Steven and Athineos, Dimitris and Nixon, Colin and Clark, William and Leach, Joshua D. G. and Sansom, Owen J. and Edwards, Joanne and Cameron, Ewan R. and Blyth, Karen},
month = jun,
year = {2020},
pmid = {32156779},
keywords = {Animals, Carcinoma, Renal Cell, Cell Growth Processes, Cell Line, Tumor, Cell Movement, Core Binding Factor Alpha 1 Subunit, Core Binding Factor Alpha 2 Subunit, Female, Gene Knockout Techniques, HEK293 Cells, Heterografts, Humans, Kidney Neoplasms, Male, Mice, Mice, Nude, Prognosis, Transcriptome},
pages = {2325--2339},
}
Downloads: 0
{"_id":"pkP3f6Ctm3gd9zj2q","bibbaseid":"rooney-mason-mcdonald-dbritz-campbell-hedley-howard-athineos-etal-runx1isadriverofrenalcellcarcinomacorrelatingwithclinicaloutcome-2020","author_short":["Rooney, N.","Mason, S. M.","McDonald, L.","Däbritz, J. H. M.","Campbell, K. J.","Hedley, A.","Howard, S.","Athineos, D.","Nixon, C.","Clark, W.","Leach, J. D. G.","Sansom, O. J.","Edwards, J.","Cameron, E. R.","Blyth, K."],"bibdata":{"bibtype":"article","type":"article","title":"RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome","volume":"80","issn":"1538-7445","doi":"10.1158/0008-5472.CAN-19-3870","abstract":"The recurring association of specific genetic lesions with particular types of cancer is a fascinating and largely unexplained area of cancer biology. This is particularly true of clear cell renal cell carcinoma (ccRCC) where, although key mutations such as loss of VHL is an almost ubiquitous finding, there remains a conspicuous lack of targetable genetic drivers. In this study, we have identified a previously unknown protumorigenic role for the RUNX genes in this disease setting. Analysis of patient tumor biopsies together with loss-of-function studies in preclinical models established the importance of RUNX1 and RUNX2 in ccRCC. Patients with high RUNX1 (and RUNX2) expression exhibited significantly poorer clinical survival compared with patients with low expression. This was functionally relevant, as deletion of RUNX1 in ccRCC cell lines reduced tumor cell growth and viability in vitro and in vivo. Transcriptional profiling of RUNX1-CRISPR-deleted cells revealed a gene signature dominated by extracellular matrix remodeling, notably affecting STMN3, SERPINH1, and EPHRIN signaling. Finally, RUNX1 deletion in a genetic mouse model of kidney cancer improved overall survival and reduced tumor cell proliferation. In summary, these data attest to the validity of targeting a RUNX1-transcriptional program in ccRCC. SIGNIFICANCE: These data reveal a novel unexplored oncogenic role for RUNX genes in kidney cancer and indicate that targeting the effects of RUNX transcriptional activity could be relevant for clinical intervention in ccRCC.","language":"eng","number":"11","journal":"Cancer Research","author":[{"propositions":[],"lastnames":["Rooney"],"firstnames":["Nicholas"],"suffixes":[]},{"propositions":[],"lastnames":["Mason"],"firstnames":["Susan","M."],"suffixes":[]},{"propositions":[],"lastnames":["McDonald"],"firstnames":["Laura"],"suffixes":[]},{"propositions":[],"lastnames":["Däbritz"],"firstnames":["J.","Henry","M."],"suffixes":[]},{"propositions":[],"lastnames":["Campbell"],"firstnames":["Kirsteen","J."],"suffixes":[]},{"propositions":[],"lastnames":["Hedley"],"firstnames":["Ann"],"suffixes":[]},{"propositions":[],"lastnames":["Howard"],"firstnames":["Steven"],"suffixes":[]},{"propositions":[],"lastnames":["Athineos"],"firstnames":["Dimitris"],"suffixes":[]},{"propositions":[],"lastnames":["Nixon"],"firstnames":["Colin"],"suffixes":[]},{"propositions":[],"lastnames":["Clark"],"firstnames":["William"],"suffixes":[]},{"propositions":[],"lastnames":["Leach"],"firstnames":["Joshua","D.","G."],"suffixes":[]},{"propositions":[],"lastnames":["Sansom"],"firstnames":["Owen","J."],"suffixes":[]},{"propositions":[],"lastnames":["Edwards"],"firstnames":["Joanne"],"suffixes":[]},{"propositions":[],"lastnames":["Cameron"],"firstnames":["Ewan","R."],"suffixes":[]},{"propositions":[],"lastnames":["Blyth"],"firstnames":["Karen"],"suffixes":[]}],"month":"June","year":"2020","pmid":"32156779","keywords":"Animals, Carcinoma, Renal Cell, Cell Growth Processes, Cell Line, Tumor, Cell Movement, Core Binding Factor Alpha 1 Subunit, Core Binding Factor Alpha 2 Subunit, Female, Gene Knockout Techniques, HEK293 Cells, Heterografts, Humans, Kidney Neoplasms, Male, Mice, Mice, Nude, Prognosis, Transcriptome","pages":"2325–2339","bibtex":"@article{rooney_runx1_2020,\n\ttitle = {{RUNX1} {Is} a {Driver} of {Renal} {Cell} {Carcinoma} {Correlating} with {Clinical} {Outcome}},\n\tvolume = {80},\n\tissn = {1538-7445},\n\tdoi = {10.1158/0008-5472.CAN-19-3870},\n\tabstract = {The recurring association of specific genetic lesions with particular types of cancer is a fascinating and largely unexplained area of cancer biology. This is particularly true of clear cell renal cell carcinoma (ccRCC) where, although key mutations such as loss of VHL is an almost ubiquitous finding, there remains a conspicuous lack of targetable genetic drivers. In this study, we have identified a previously unknown protumorigenic role for the RUNX genes in this disease setting. Analysis of patient tumor biopsies together with loss-of-function studies in preclinical models established the importance of RUNX1 and RUNX2 in ccRCC. Patients with high RUNX1 (and RUNX2) expression exhibited significantly poorer clinical survival compared with patients with low expression. This was functionally relevant, as deletion of RUNX1 in ccRCC cell lines reduced tumor cell growth and viability in vitro and in vivo. Transcriptional profiling of RUNX1-CRISPR-deleted cells revealed a gene signature dominated by extracellular matrix remodeling, notably affecting STMN3, SERPINH1, and EPHRIN signaling. Finally, RUNX1 deletion in a genetic mouse model of kidney cancer improved overall survival and reduced tumor cell proliferation. In summary, these data attest to the validity of targeting a RUNX1-transcriptional program in ccRCC. SIGNIFICANCE: These data reveal a novel unexplored oncogenic role for RUNX genes in kidney cancer and indicate that targeting the effects of RUNX transcriptional activity could be relevant for clinical intervention in ccRCC.},\n\tlanguage = {eng},\n\tnumber = {11},\n\tjournal = {Cancer Research},\n\tauthor = {Rooney, Nicholas and Mason, Susan M. and McDonald, Laura and Däbritz, J. Henry M. and Campbell, Kirsteen J. and Hedley, Ann and Howard, Steven and Athineos, Dimitris and Nixon, Colin and Clark, William and Leach, Joshua D. G. and Sansom, Owen J. and Edwards, Joanne and Cameron, Ewan R. and Blyth, Karen},\n\tmonth = jun,\n\tyear = {2020},\n\tpmid = {32156779},\n\tkeywords = {Animals, Carcinoma, Renal Cell, Cell Growth Processes, Cell Line, Tumor, Cell Movement, Core Binding Factor Alpha 1 Subunit, Core Binding Factor Alpha 2 Subunit, Female, Gene Knockout Techniques, HEK293 Cells, Heterografts, Humans, Kidney Neoplasms, Male, Mice, Mice, Nude, Prognosis, Transcriptome},\n\tpages = {2325--2339},\n}\n\n\n\n\n\n\n\n\n\n\n\n","author_short":["Rooney, N.","Mason, S. M.","McDonald, L.","Däbritz, J. H. M.","Campbell, K. J.","Hedley, A.","Howard, S.","Athineos, D.","Nixon, C.","Clark, W.","Leach, J. D. G.","Sansom, O. J.","Edwards, J.","Cameron, E. R.","Blyth, K."],"key":"rooney_runx1_2020","id":"rooney_runx1_2020","bibbaseid":"rooney-mason-mcdonald-dbritz-campbell-hedley-howard-athineos-etal-runx1isadriverofrenalcellcarcinomacorrelatingwithclinicaloutcome-2020","role":"author","urls":{},"keyword":["Animals","Carcinoma","Renal Cell","Cell Growth Processes","Cell Line","Tumor","Cell Movement","Core Binding Factor Alpha 1 Subunit","Core Binding Factor Alpha 2 Subunit","Female","Gene Knockout Techniques","HEK293 Cells","Heterografts","Humans","Kidney Neoplasms","Male","Mice","Mice","Nude","Prognosis","Transcriptome"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero-group/VHLA/5946245","dataSources":["ePsAR3pjtvuSxA4wN"],"keywords":["animals","carcinoma","renal cell","cell growth processes","cell line","tumor","cell movement","core binding factor alpha 1 subunit","core binding factor alpha 2 subunit","female","gene knockout techniques","hek293 cells","heterografts","humans","kidney neoplasms","male","mice","mice","nude","prognosis","transcriptome"],"search_terms":["runx1","driver","renal","cell","carcinoma","correlating","clinical","outcome","rooney","mason","mcdonald","däbritz","campbell","hedley","howard","athineos","nixon","clark","leach","sansom","edwards","cameron","blyth"],"title":"RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome","year":2020}